Developer docs
API playgroundTry for free, no card

Search company profiles

Adamas Pharmaceuticals

Full company profile

uuid0005b91

Namestring
Adamas Pharmaceuticals
Legal namestring
Supernus Pharmaceuticals, Inc.
Company typeenum
Public
Founded yearint
2000
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
controlled release therapeutics, combination therapeutics, CNS disorder treatments, infectious disease therapeutics, specialty pharmaceuticals
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Qelbree
Description

FDA-approved product for the treatment of ADHD, a CNS condition.

supernus.com
Core offering1 text field

Adamas Pharmaceuticals develops and commercializes controlled release combination therapeutics targeting infectious diseases and central nervous system (CNS) disorders. The company applies proprietary drug formulation and pharmacokinetic engineering to create dosing regimens intended to improve adherence, symptom control, and clinical outcomes in chronic neurological and infectious disease indications.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Controlled release combination therapeutics for CNS and infectious diseases
CategorySpecialty Pharmaceuticals
Description

Therapeutic products engineered with controlled-release pharmacokinetics and combination drug approaches targeting infectious diseases and central nervous system disorders. Distributed to healthcare providers and through specialty pharmacy channels for patient use under prescription.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public US specialty pharma focused on neurology and psychiatry products. Direct peer in CNS indication focus, specialty-pharma commercial model, and public-market scale.

TypeDirect peer
Description

Public specialty pharma with a strong CNS/neurology franchise (including narcolepsy and epilepsy products). Comparable to Adamas in CNS therapeutic focus and specialty-pharma commercial scale.

TypeDirect peer
Description

Specialty pharmaceutical company commercializing CNS therapies including treatments for Parkinson's disease psychosis and Rett syndrome. Overlaps Adamas on neurology indication targeting and specialty commercial model.

TypeBroad incumbent
Description

Large generic and specialty pharmaceutical company with a meaningful CNS portfolio including Parkinson's disease treatments. Comparable on CNS therapeutic area and combination/specialty-pharma business lines, but much broader in scale and product mix.

TypeBroad incumbent
Description

Global pharmaceutical company specializing exclusively in brain diseases including neurology and psychiatry. Comparable CNS-focused portfolio and specialty-pharma model, but operates as a broad incumbent across multiple CNS indications.

TypeDirect peer
Description

Public CNS-focused specialty pharmaceutical company with marketed CNS products and a development pipeline. Highly comparable to Adamas on therapeutic area (CNS), commercial-stage business model, and specialty-pharma go-to-market.

TypeBroad incumbent
Description

Global pharmaceutical company with a CNS franchise (including psychiatry and neurology products). Overlaps Adamas in CNS specialty-pharma development and commercialization, but operates across many therapeutic areas.

TypeEmerging player
Description

Smaller clinical-stage biotechnology company developing therapeutics for CNS and infectious disease indications. Comparable on therapeutic-area overlap with Adamas (CNS + infectious disease), though at earlier stage.

TypeBroad incumbent
Description

Global biopharmaceutical company with a significant neurology/CNS franchise (epilepsy, Parkinson's). Comparable CNS indication coverage, but at a larger, more diversified scale than Adamas.

TypeDirect peer
Description

CNS-focused biopharmaceutical company developing therapies for CNS conditions (now part of Supernus). Direct peer on therapeutic-area focus and specialty CNS development model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adamas Pharmaceuticals

Specialty Pharmaceuticalsadamaspharma.com

Adamas Pharmaceuticals firmographics

Firmographics
Name
Adamas Pharmaceuticals
Legal name
Supernus Pharmaceuticals, Inc.
Website
https://adamaspharma.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Adamas Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Controlled release therapeutics
  • Combination therapeutics
  • CNS disorder treatments
  • Infectious disease therapeutics
  • Specialty pharmaceuticals

Where Adamas Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Markets served

Adamas Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Adamas Pharmaceuticals product offering

Product offering

Core offering

Adamas Pharmaceuticals develops and commercializes controlled release combination therapeutics targeting infectious diseases and central nervous system (CNS) disorders. The company applies proprietary drug formulation and pharmacokinetic engineering to create dosing regimens intended to improve adherence, symptom control, and clinical outcomes in chronic neurological and infectious disease indications.

Differentiator

Problem solved

Functional benefit

Brands

  • Qelbree: FDA-approved product for the treatment of ADHD, a CNS condition.

Products and services

  • Controlled release combination therapeutics for CNS and infectious diseases Therapeutic products engineered with controlled-release pharmacokinetics and combination drug approaches targeting infectious diseases and central nervous system disorders. Distributed to healthcare providers and through specialty pharmacy channels for patient use under prescription.

Companies that use Adamas Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Adamas Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Adamas Pharmaceuticals partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights4 records

Adamas Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Neurocrine Biosciences: Public US specialty pharma focused on neurology and psychiatry products. Direct peer in CNS indication focus, specialty-pharma commercial model, and public-market scale.
  • Jazz Pharmaceuticals: Public specialty pharma with a strong CNS/neurology franchise (including narcolepsy and epilepsy products). Comparable to Adamas in CNS therapeutic focus and specialty-pharma commercial scale.
  • Acadia Pharmaceuticals: Specialty pharmaceutical company commercializing CNS therapies including treatments for Parkinson's disease psychosis and Rett syndrome. Overlaps Adamas on neurology indication targeting and specialty commercial model.
  • Supernus Pharmaceuticals: Public CNS-focused specialty pharmaceutical company with marketed CNS products and a development pipeline. Highly comparable to Adamas on therapeutic area (CNS), commercial-stage business model, and specialty-pharma go-to-market.
  • Sage Therapeutics: CNS-focused biopharmaceutical company developing therapies for CNS conditions (now part of Supernus). Direct peer on therapeutic-area focus and specialty CNS development model.

Broad incumbents

  • Teva Pharmaceutical Industries: Large generic and specialty pharmaceutical company with a meaningful CNS portfolio including Parkinson's disease treatments. Comparable on CNS therapeutic area and combination/specialty-pharma business lines, but much broader in scale and product mix.
  • Lundbeck: Global pharmaceutical company specializing exclusively in brain diseases including neurology and psychiatry. Comparable CNS-focused portfolio and specialty-pharma model, but operates as a broad incumbent across multiple CNS indications.
  • Otsuka Pharmaceutical: Global pharmaceutical company with a CNS franchise (including psychiatry and neurology products). Overlaps Adamas in CNS specialty-pharma development and commercialization, but operates across many therapeutic areas.
  • UCB: Global biopharmaceutical company with a significant neurology/CNS franchise (epilepsy, Parkinson's). Comparable CNS indication coverage, but at a larger, more diversified scale than Adamas.

Emerging players

  • Inhibikase Therapeutics: Smaller clinical-stage biotechnology company developing therapeutics for CNS and infectious disease indications. Comparable on therapeutic-area overlap with Adamas (CNS + infectious disease), though at earlier stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Adamas Pharmaceuticals social profiles

Digital presence

Adamas Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adamas Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Adamas Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Adamas Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adamas Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adamas Pharmaceuticals

What does Adamas Pharmaceuticals do?

Adamas Pharmaceuticals develops and commercializes controlled release combination therapeutics targeting infectious diseases and central nervous system (CNS) disorders. The company applies proprietary drug formulation and pharmacokinetic engineering to create dosing regimens intended to improve adherence, symptom control, and clinical outcomes in chronic neurological and infectious disease indications.

Is Adamas Pharmaceuticals a public or private company?

Adamas Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Adamas Pharmaceuticals founded?

Adamas Pharmaceuticals was founded in 2000. It employs 51 to 100 people.

Where is Adamas Pharmaceuticals based?

Adamas Pharmaceuticals is headquartered in Emeryville, United States, in the North America region.

Who are Adamas Pharmaceuticals's main competitors?

Direct peers on record are Neurocrine Biosciences, Jazz Pharmaceuticals, Acadia Pharmaceuticals, Supernus Pharmaceuticals and Sage Therapeutics. Broad incumbents are Teva Pharmaceutical Industries, Lundbeck, Otsuka Pharmaceutical and UCB. Inhibikase Therapeutics is listed as an emerging player.

Does Adamas Pharmaceuticals have an API?

No public API is recorded for Adamas Pharmaceuticals.

What industry is Adamas Pharmaceuticals in?

Adamas Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMSThe United States District Court for the Northern District of California has approved a class action settlement notice for purchasers of Adamas Pharmaceuticals, Inc. common stock between August 8, 2017 and March 4, 2019. The proposed settlement amounts to $4,650,000 in cash to resolve all claims in the litigation. A settlement fairness hearing is scheduled for August 30, 2024 before Judge Jeffrey S. White in Oakland, California.PR NewswireGlobal Tardive Dyskinesia Therapeutics Market Analysis & Forecast 2024-2034 - Hospital Pharmacies Lead Distribution ChannelsResearchAndMarkets.com has released a market analysis report on the global tardive dyskinesia therapeutics market, projecting growth from USD 3.59 billion in 2023 to USD 9.56 billion by 2034, representing a compound annual growth rate of 9.31%. Valbenazine led revenue in 2023, while hospital pharmacies held the largest distribution channel share, with North America currently dominating the market and Asia Pacific expected to see exponential growth. The report profiles key companies in the competitive landscape including Neurocrine Biosciences, Teva Pharmaceutical, AbbVie, and Sun Pharmaceutical Industries.BioSpaceSupernus Pharmaceuticals Completes Acquisition of Adamas PharmaceuticalsSupernus Pharmaceuticals has completed its acquisition of Adamas Pharmaceuticals, purchasing all outstanding shares through a tender offer and subsequent merger. The transaction includes a cash payment of $8.10 per share plus contingent value rights, aiming to diversify Supernus's revenue base by adding Parkinson's disease treatments GOCOVRI and Osmolex ER. Supernus expects the deal to be accretive in 2022 with potential synergies ranging from $60 million to $80 million.PR NewswireADAMAS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. -Kahn Swick & Foti, LLC is investigating the proposed sale of Adamas Pharmaceuticals to Supernus Pharmaceuticals to determine if the consideration offered to shareholders is adequate. Under the transaction terms, Adamas shareholders will receive $8.10 in cash plus contingent value rights potentially worth up to $1.00 per share.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the FirmInvestor rights law firm Halper Sadeh LLP announced it is investigating four companies regarding potential violations of federal securities laws and breaches of fiduciary duties in connection with their respective acquisition transactions. The four companies under scrutiny are FTS International (being acquired by ProFrac Holdings for $26.52 per share), Umpqua Holdings (being acquired by Columbia Banking System in an all-stock deal giving Umpqua shareholders 62% of the combined company), Flexion Therapeutics (being acquired by Pacira BioSciences for $8.50 cash plus CVRs up to $8.00 per share), and Adamas Pharmaceuticals (being acquired by Supernus Pharmaceuticals for $8.10 cash plus CVRs up to $1.00 per share). The law firm stated it may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.PR NewswireSHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing InvestigationsWeissLaw LLP announced ongoing investigations into possible breaches of fiduciary duty by the boards of four companies in connection with proposed acquisitions: Adamas Pharmaceuticals (being acquired by Supernus Pharmaceuticals for $8.10 cash plus CVRs up to $1.00 per share), Flexion Therapeutics (being acquired by Pacira BioSciences for $8.50 cash plus CVRs up to $8.00 per share), Aspen Technology (merging with Emerson Electric's industrial software businesses for ~$87 cash plus 0.42 shares per share), and Eagle Bancorp Montana (acquiring First Community Bancorp for $276.32 cash plus 37.75 EBMT shares per share). The law firm is inviting shareholders of these companies to contact them to discuss the investigations or their rights.PR NewswireShareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with SupernusAdemi LLP is investigating Adamas Pharmaceuticals for possible breaches of fiduciary duty in its Supernus merger. The deal pays $8.10 per share in cash plus two CVRs worth up to $1.00 per share, totaling $9.10 per share. The firm alleges the merger limits competing bids and insiders receive substantial benefits.BenzingaMid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas PharmaceuticaSupernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals for $9.10 per share in a deal valued at approximately $450 million, including $8.10 in cash and up to $1.00 in contingent value rights per share. The announcement drove Adamas Pharmaceuticals shares up 75% to $8.09, approaching the deal price. Separately, crude oil futures surged 2.3% to $81.17 per barrel, while the broader market indices posted modest gains with the Dow up 0.50%.Benzinga28 Stocks Moving In Monday's Mid-Day SessionOn Monday's mid-day trading session, multiple stocks posted significant gains led by Protagonist Therapeutics surging 85% after the FDA removed a full clinical hold on its rusfertide studies and Northland upgraded the stock, while Adamas Pharmaceuticals jumped 74% following news of its acquisition by Supernus Pharmaceuticals for $450 million. Additional notable movers included Flexion Therapeutics climbing 60.9% on acquisition by Pacira BioSciences and Ocular Therapeutix rising 15% amid circulating news of FDA approval for its Dextenza product. On the losing side, Cipher Mining fell 18.8%, AeroCentury Corp. dropped 14%, and SecureWorks declined 13.3%, while Hyliion Holdings fell 9% after UBS downgraded the stock to Sell.BenzingaSupernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights - Supernus Pharmaceuticals (Supernus Pharmaceuticals has agreed to acquire Adamas Pharmaceuticals for $450 million ($9.10 per share) in a deal combining $8.10 in cash and up to $1.00 in contingent value rights. The acquisition brings Gocovri, the first and only FDA-approved medicine for OFF episodes and dyskinesia in Parkinson's disease patients on levodopa therapy, along with Osmolex ER. The companies expect synergies of $60-80 million in the first year and anticipate the deal to be significantly accretive to earnings in 2022.